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DementiaNeuroinﬂammation may be involved in the pathophysiology of Parkinson’s disease (PD) and speciﬁcally
in non-motor symptoms such as depression, fatigue and cognitive impairment. The aim of this study was
to measure inﬂammatory markers in cerebrospinal ﬂuid (CSF) samples from PD patients and a reference
group, and to investigate correlations between non-motor symptoms and inﬂammation.
We quantiﬁed C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, eotaxin, interferon
gamma-induced protein-10, monocyte chemotactic protein-1 (MCP-1), and macrophage inﬂammatory
protein 1-b in CSF samples from PD patients (N = 87) and the reference group (N = 33). Sixteen of the
PD patients had a dementia diagnosis (PDD). We assessed symptoms of fatigue, depression, anxiety
and cognitive function using the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital
Anxiety and Depression Scale, and the Mini Mental State Examination, respectively.
There were no signiﬁcant differences in mean levels of inﬂammatory markers between PD patients and
the reference group. After controlling for age, gender and somatic illness, patients with PDD had signif-
icantly higher levels of CRP compared to non-demented PD patients (p = 0.032) and the reference group
(p = 0.026). Increased levels of inﬂammatory markers in CSF were signiﬁcantly associated with more
severe symptoms of depression, anxiety, fatigue, and cognition in the entire PD group. After controlling
for PD duration, age, gender, somatic illness and dementia diagnosis, high CRP levels were signiﬁcantly
associated with more severe symptoms of depression (p = 0.010) and fatigue (p = 0.008), and high
MCP-1 levels were signiﬁcantly associated with more severe symptoms of depression (p = 0.032).
Our results indicate that non-motor features of PD such as depression, fatigue, and cognitive impair-
ment are associated with higher CSF levels of inﬂammatory markers.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Parkinson’s disease (PD) is one of the most common neurode-
generative diseases with causes still largely unknown. Results from
pre-clinical and epidemiological studies suggest that neuroinﬂam-
mation may play an important role in the death of dopaminergic
neurons in the substantia nigra, which is the pathological hallmark
of PD (Barnum and Tansey, 2010). Also, in vivo and post-mortem
studies of PD patients have described microglial activation in the
putamen, hippocampus and in frontal and temporal cortical re-
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studies have indeed shown that PD patients display signiﬁcantly
higher blood levels of pro-inﬂammatory (Dobbs et al., 1999; Lindq-
vist et al., 2012; Scalzo et al., 2010), although some studies have
also reported negative results (Scalzo et al., 2011).
The few previous studies investigating inﬂammatory markers in
the cerebrospinal ﬂuid (CSF) of PD patients have been conducted
on comparatively small numbers of subjects, and often without a
healthy control group for comparison. Blum-Degen et al. reported
signiﬁcantly higher CSF, but not plasma, levels of IL-6 and IL-1-beta
in 22 de novo PD patients compared to 12 patients with other neu-
rological disorders (Blum-Degen et al., 1995). Mogi et al. found
higher levels of TNF-alpha in CSF samples and post-mortem tissue
from 15 parkinsonian patients compared to 16 controls (Mogi
et al., 1994). Interestingly, neuroinﬂammation has not only been
implicated in PD per se, but more speciﬁcally in the generation
of non-motor symptoms (Barnum and Tansey, 2012). Non-motor
symptoms such as depression, anxiety, fatigue, and cognitive de-
cline are frequently occurring in PD (Aarsland et al., 2009) and
may in fact be even stronger determinants of low quality of life
and poor health status than motor symptoms (Hinnell et al.,
2012; McKinlay et al., 2008; Soh et al., 2011). Serum (Lindqvist
et al., 2012) and plasma (Menza et al., 2010) levels of cytokines
have been found to correlate with symptoms of depression, fatigue,
and cognitive difﬁculties in PD, but no previous studies have inves-
tigated inﬂammatory markers in CSF in relation to such symptoms.
To date, the pathophysiological mechanisms behind non-motor
symptoms of PD are poorly understood, and current treatment op-
tions are in many cases inadequate (Aarsland et al., 2009; Wein-
traub et al., 2005). By investigating associations between
inﬂammatory markers and non-motor symptoms we hope to gain
further insight into this area, which in turn could open up the pos-
sibility of novel treatment options. In this study we set out to
quantify inﬂammatory markers in CSF of patients with PD
(n = 87) and a reference group (n = 33), all evaluated for fatigue,
depression, anxiety and cognitive function. As opposed to mea-
surements of immune markers in blood samples, this approach
aims to link PD symptomatology directly to signs of neuroinﬂam-
mation. To the best of our knowledge, this is the largest study mea-
suring inﬂammatory markers in the CSF of PD patients and a
reference group, and the ﬁrst to investigate correlations betweenTable 1
Demographic characteristics and inﬂammatory markers of the reference group, non-demen
where concentrations are given in ng/ml. Raw values of inﬂammatory markers and clinica
Controls (n = 33)
Sex f = 19 (58%), m = 14
Age (years, mean ± SD) 65.8 ± 8.8
Illness duration (years, mean ± SD) N/A
Hoehn and Yahr (mean ± SD) N/A
Schwab and England (median, IQL) 100, 100–100
UPDRS motor score (median, IQL) 0, 0–2
FACIT-fatigue score (median, IQL) 51, 50–52
HADS depression score (median, IQL) 0, 0–1
HADS anxiety score (median, IQL) 1, 0–3
MMSE score (median, IQL) 29, 28–30
Eotaxin (median, IQR) 22.0, 18.5–27.5
MIP-1b (median, IQR) 9.6, 5.4–17.5
IP-10 (median, IQR) 295, 204–412
MCP-1 (median, IQR) 585, 488–673
IL-6 (median, IQR) 0.8, 0.6–1.1
TNF-alpha (median, IQR) 0.07, 0.04–0.08
CRP (median, IQR) 19.7, 8.6–53.9
Abbreviations: UPDRS = uniﬁed Parkinson’s disease rating scale, FACIT = functional asse
MMSE = mini mental state examinations, MCP = monocyte chemotactic protein, CRP = C-r
induced protein, MIP = macrophage inﬂammatory protein.
a PDD patients differed signiﬁcantly from both non-demented PD patients and health
b Non-demented PD patients differed signiﬁcantly from healthy controls (p < 0.05).non-motor symptoms and neuroinﬂammation in PD patients. We
hypothesized that PD patients would have higher mean levels of
inﬂammatory markers than those in the reference group and that
the highest levels would be observed in those with more severe
symptoms of depression, anxiety, fatigue, and cognitive
impairment.2. Methods
2.1. Study participants
Eighty-seven PD patients were enrolled in this study between
the years 2008 and 2012. Sixteen of these patients suffered from
Dementia in PD (PDD). PD patients were recruited to the Skåne
University Hospital in Lund, Sweden from neurological clinics in
southern Sweden.
Thirty-three individuals comprising the reference group were
mainly recruited by contacting spouses of PD patients but also by
recruitment during public lectures.
Twenty-ﬁve (76%) of the individuals comprising the reference
group were spouses of patients, and two (6%) were blood relatives.
None of the participants in the reference group had a neurological
disease, suffered from dementia, or had any signs of ongoing
depression.
None of the study participants were treated with NSAIDs or cor-
ticosteroids or had any acute or chronic inﬂammatory disease. The
most common somatic disorders were: cardiovascular disease (PD
patients N = 18 [21%]; Reference group N = 12 [36%]), asthma/aller-
gies (PD patients N = 10 [12%]; Reference group N = 2 [6%]), osteo-
arthritis (PD patients N = 8 [9%]; Reference group N = 4 [12%]), and
diabetes mellitus (PD patients N = 3 [3%]; Reference group N = 1
[3%]). Demographic characteristics of non-demented PD patients,
PDD patients and the reference group are given in Table 1. Mean
age was signiﬁcantly higher in the PDD group compared to the
non-demented PD and the reference group (F(2,117) = 4.44,
p = 0.014; PDD vs non-demented PD, p = 0.005; PDD vs the refer-
ence group p = 0.013). The gender distribution differed borderline
signiﬁcantly between the groups (Pearson’s X2 = 5.7, p = 0.059),
with a higher proportion of men in the PD groups. A signiﬁcantly
larger proportion of the PDD patients received antidepressantsted PD patients, and PDD patients. Concentrations are given in pg/ml, except for CRP
l variables are presented.
Non-demented PD (n = 71) PDD (n = 16) P-value
f = 27 (39%), m = 44 f = 4 (22%), m = 12 .059
64.1 ± 10.5 72.0 ± 5.8a .014
6.4 ± 5.6 15.8 ± 6.5 .00
1.9 ± 0.8 3.1 ± 0.9 .00
90, 90–100b 70, 63–80a .00
18, 10–25b 32, 23–50a .00
43, 34–47b 29, 14–40a .00
3, 1–5b 8, 5–10a .00
4, 2–7b 6, 4–8a .00
29, 27–29 25, 21–27a .00
23.8, 20.3–30.4 23.0, 19.6–28.8 .50
7.9, 5.0–12.8 8.4, 5.0–12.7 .56
302, 221–453 381, 234–488 .54
583, 509–687 637, 531–864 .29
0.7, 0.5–1.1 1.0, 0.7–1.1 .22
0.07, 0.03–0.10 0.06, 0.04–0.10 0.94
22.8, 8.2–51.7 57.1, 18.3–246.1a .038
ssment of chronic illness therapy, HADS = hospital anxiety and depression scale,
eactive protein, IL = interleukin, TNF = tumor necrosis factor, IP = interferon gamma-
y controls (p < 0.05).
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group (Pearson’s X2 = 19.1, p < 0.001).2.2. Ethics statement
The Ethics Committee of Lund University approved this study.
Study participants gave written informed consent to participate.
The study was conducted in accordance with the provisions of
the Helsinki Declaration.2.3. Study procedures/assessments
All study participants underwent a general physical examina-
tion, routine blood screening and complete medical history was ta-
ken. All study participants were evaluated by a licensed and
experienced medical doctor using the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS)-3 (Fahn et al., 1987), the Hoehn & Yahr scale
(Hoehn and Yahr, 1967), and the Schwab & England scale (Schwab
and England, 1969). PD diagnosis was veriﬁed according to the Na-
tional Institute of Neurological Disorders and Stroke diagnostic cri-
teria (Gelb et al., 1999). PDD was diagnosed according to the
Clinical Diagnostic Criteria for Dementia Associated with PD (Emre
et al., 2007).
All study participants were asked to complete Functional
Assessment of Chronic Illness Therapy (FACIT)-Fatigue (Cella,
1997) and the Hospital Anxiety and Depression Scale (HADS) (Zig-
mond and Snaith, 1983). Mini Mental State Examinations (MMSE)
were performed by a trained clinician (Folstein et al., 1975).
HADS scores were missing for three individuals and FACIT fati-
gue scores for 9 individuals. Non-motor symptom scores of non-
demented PD patients, PDD patients and the reference group are
given in Table 1.2.4. CSF sampling and biological assays
Lumbar punctures were carried out in the morning following
the clinical evaluation. Approximately 20 ml CSF were collected
between L3 and L4, L4 and L5, or L5 and S1. CSF was collected in
polypropylene tubes and gently mixed to avoid gradient effects.
All samples were centrifuged within 30 min at +4 C at 2000g for
10 min to remove cells and debris. Samples were stored in aliquots
at 80 C pending biochemical analysis.
C-reactive protein (CRP), interleukin-6 (IL-6), eotaxin, tumor
necrosis factor (TNF)-alpha, interferon gamma-induced protein-
10 (IP-10), monocyte chemotactic protein-1 (MCP-1), and macro-
phage inﬂammatory protein-1b (MIP-1b) levels in CSF were quan-
tiﬁed using multiplex electrochemiluminescence-based
immunoassays (MesoScale Discovery, Gaithersburg, Maryland,
USA) as per the manufacturer’s protocol with small modiﬁcations.
Brieﬂy, 10% bovine serum albumin (Fisher Scientiﬁc, Gothenburg,
Sweden) was added to the blocking buffer and 50 ll of undiluted
sample per replicate was used in the assay. For CRP, however,
based on the data from the pilot experiment, 25 ll of samples
was used. All the samples were measured in duplicates on the
same day using the same reagents. Data was collected and ana-
lyzed using SECTOR Imager 6000 reader and Discovery Work-
bench Software (www.mesoscale.com). Detection limits of the
assay were: CRP, 7 pg/ml; IL-6, 0.03 pg/ml; TNF-alpha, 0.04 pg/
ml; Eotaxin 3.4 pg/ml; IP-10, 0.99 pg/ml; MIP-1b, 5.76 pg/ml;
MCP-1, 0.17 pg/ml. Intra-assay CV was below 20% for all samples.
Serum levels of CRP, TNF-alpha, and IL-6 have previously been
quantiﬁed in this sample of PD patients and in the reference group
using methods described elsewhere (Lindqvist et al., 2012).2.5. Statistical analyses
The Statistical Package for the Social Sciences (SPSS) for Mac
was used for statistical calculations. Pearson’s X2 was used to com-
pare proportions. Student’s T-test and one-way analysis of variance
(ANOVA) was used for group comparisons, controlling for covari-
ates when appropriate (full factorial ANCOVA). Non-normally dis-
tributed variables were transformed into their natural logarithms
prior to statistical analyses with parametric methods and in cases
when log transformation did not result in normal distribution,
non-parametric methods were used for univariate group compari-
sons (Kruskal–Wallis non-parametric ANOVA or Mann–Whitney
U-test). Univariate associations between two continuous variables
were analyzed using the Pearson’s r (normally distributed vari-
ables) or Spearman’s Rho (skewed variables and/or ordinal data).
To further explore signiﬁcant correlations between levels of
inﬂammatory markers and symptom severity, hierarchical multi-
ple regressions were carried out, controlling for appropriate covar-
iates as described below. The respective non-motor symptom score
was entered as dependent variable in each model. Total somatic ill-
ness, age, gender, PDD diagnosis (except in the case of MMSE
scores), and PD duration were entered into the ﬁrst block as inde-
pendent variables, and the inﬂammatory marker of interest was
subsequently entered into the second block. There was one outlier
on FACIT-fatigue scores, two outliers on HADS depression scores,
three outliers on HADS anxiety scores, and nine outliers on MMSE
scores. Hierarchical multiple regressions were carried out both
with and without outliers, and results from both analyses are given
in the results section.
All tests were 2-tailed with an alpha = 0.05, P-values between
0.05 and 0.1 were considered trends.2.6. Rationale for selecting covariates
Based on our hypotheses that more severe somatic co-morbid-
ity could potentially inﬂuence both inﬂammatory markers and
non-motor symptom severity, ‘‘total somatic illness’’ was selected
a priori as a covariate. This was a continuous variable calculated as
a composite score of all of the most common somatic co-morbidi-
ties for each individual. The following variables correlated signiﬁ-
cantly (or near-signiﬁcantly) with non-motor symptoms and/or
inﬂammatory markers in bivariate analyses: Age, gender, PD dura-
tion in years, and PDD diagnosis. Thus, these variables were also
entered as covariates in all analyses investigating associations be-
tween severity of non-motor symptoms and levels of inﬂammatory
markers. PDD diagnosis was not controlled for in analyses between
inﬂammatory markers and cognitive performance. Variables
UPDRS-3 score, Schwab & England score, and PD duration were
all highly inter-correlated (all Spearman’s Rho > 0.7, p < 0.001),
seemingly sharing variance. Since PD duration was normally dis-
tributed after log-transformation (as opposed to UPDRS-score
and Schwab & England score) we used this variable as a proxy
for ‘‘general burden of illness’’.3. Results
3.1. Demographics
Demographic and clinical characteristics of the reference group,
non-demented PD patients, and PDD patients are given in Table 1.
In the entire group, age was signiﬁcantly correlated with MCP-1
(Spearman’s Rho = 0.37, p < 0.001), IP-10 (Spearman’s Rho = 0.23,
p = 0.01) and CRP (Pearson’s r = 0.30, p = 0.001). Moreover, men
had signiﬁcantly higher mean levels of eotaxin (t(117) = 2.7,
p = 0.009), and MCP-1 (Mann–Whitney U = 1309, p < 0.02). Total
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man’s Rho = 0.19, p = .04) and positively with CRP levels (Spear-
man’s Rho = 0.18, p = .059). UPDRS motor score correlated
positively with CRP (Spearman’s Rho = 0.21, p = 0.023) and MCP-1
(Spearman’s Rho = 0.16, p = .08). In the PD group, illness duration
was correlated with CRP (Pearson´s r = 0.21, p = 0.054). PD staging,
according to the Hoehn & Yahr scale correlated positively with
CRP (Spearman’s Rho = 0.28, p = .0011) and MIP-1 beta (Spear-
man’s Rho = 0.18, p = .092). Status as a de novo PD patient had no
signiﬁcant impact on any of the measured biomarkers (data not
shown).
3.2. Group comparisons, CSF inﬂammatory markers
There were no signiﬁcant differences (or trends) in mean or
median scores for any of the measured inﬂammatory markers be-
tween PD patients (n = 87) and the reference group (n = 33) (Stu-
dent T-tests, Mann Whitney U tests, ANCOVA’s, all non signiﬁcant
(NS)).
Mean CRP levels were signiﬁcantly higher in the PDD group
compared to the non-demented PD patients and the reference
group (F(2,112) = 3.36, p = 0.038; PDD patients vs non-demented
PD patients, p = 0.018; PDD patients vs the reference group,
p = 0.017). There were no signiﬁcant differences in mean or median
levels for any of the other cytokines between PD patients without
dementia (n = 71), PDD patients (n = 16) and the reference group
(n = 33) (One-way ANOVA’s and Kruskal Wallis non-parametric
ANOVA’s, NS) (Table 1). After controlling for the effects of age, gen-
der, and total somatic illness, PDD patients displayed signiﬁcantly
higher mean levels of CRP compared to the reference group
(p = 0.026) and the non-demented PD patients (p = 0.032). There
were no signiﬁcant differences in any of the other inﬂammatory
markers between PDD patients, non-demented PD patients and
the reference group (data not shown). After excluding two of the
individuals in the reference group whom were blood relatives to
PD patients, the p-values in all analyses were similar.
3.3. Associations between inﬂammatory markers and non-motor
symptoms in PD patients
Table 2 summarizes all univariate correlations between severity
of non-motor symptoms and CSF inﬂammatory markers in the PD
group. HADS depression score correlated signiﬁcantly and posi-
tively with CRP (Spearman’s Rho = 0.33, p = 0.002), and MCP-1
(Spearman’s Rho = 0.34, p = 0.001). HADS anxiety score correlated
signiﬁcantly and positively with IP-10 (Spearman’s Rho = 0.22,
p = 0.040). MMSE score correlated signiﬁcantly with IL-6 levels
(Spearman’s Rho = 0.27 p = 0.013). MMSE score did not correlate
signiﬁcantly with any of the other measured inﬂammatory bio-Table 2
Univariate correlations between non-motor symptom scores and CSF inﬂammatory
markers in all PD patients. Spearman’r Rho was used, correlation coefﬁcients are
given. Since FACIT is an inverse rating scale, a negative correlation herein indicates
that the patients with higher levels of inﬂammatory markers display more severe
fatigue.
HADS depression HADS anxiety FACIT-fatigue MMSE
CRP .33b .12 .32b .09
IL-6 .03 .03 .11 .27a
TNF-alpha .01 .06 .04 .01
Eotaxin .02 .10 .00 .05
MCP-1 .34b .09 .30b .13
MIP-1beta .05 .07 .06 .04
IP-10 .12 .22a .32b .03
a p < 0.05.
b p < 0.01.markers (all p-values >0.25, see Table 2). FACIT-fatigue score corre-
lated signiﬁcantly and negatively with CRP (Spearman’s
Rho = 0.32 p = 0.004), IP-10 (Spearman’s Rho = 0.32, p = 0.004),
and MCP-1 (Spearman’s Rho = 0.30 p = 0.006). Since FACIT is an
inverse rating scale, a negative correlation herein indicates that
the patients with higher levels of inﬂammatory markers display
more severe fatigue.
None of these correlations were signiﬁcant in the reference
group, although FACIT-fatigue score were borderline signiﬁcantly
associated with IP-10 (Spearman’s Rho = 0.34, p = 0.068) and
CRP (Spearman’s Rho = 0.36, p = 0.063). All of the correlations
above were in the hypothesized direction, i.e. more severe non-
motor symptoms were associated with increased levels of inﬂam-
matory markers in CSF.
Univariate correlations between CRP and HADS depression
score and FACIT-fatigue score are shown in Figs. 1 and 2.
In order to further explore the signiﬁcant correlations, we car-
ried out hierarchical multiple regressions, controlling for total so-
matic illness, PD duration, age, gender, and PDD diagnosis.
FACIT score as dependent variable: CRP (b = 0.29, p = 0.008),
IP-10 (b = 0.25, p = 0.015), but not MCP-1 (b = 0.16, p = 0.19) re-
mained signiﬁcantly associated with FACIT scores. After excluding
one outlier on FACIT-fatigue, CRP (b = 0.22, p = 0.035), but not IP-
10 (b = 0.17, p = 0.087) or MCP-1 (b = 0.13, p = 0.26) remained
signiﬁcantly associated with FACIT-fatigue scores.
HADS depression score as dependent variable: CRP (b = 0.28,
p = 0.010) and MCP-1 (b = 0.26, p = 0.032) remained signiﬁcantly
associated with high HADS depression scores. After excluding
two HADS depression outliers both CRP (b = 0.21, p = 0.041) and
MCP-1 (b = 0.27, p = 0.013) were signiﬁcantly associated with
HADS depression scores.
HADS anxiety score as dependent variable: IP-10 was not signif-
icantly associated with HADS anxiety scores either before (b = 0.18,
p = 0.10) or after (b = 0.13, p = 0.26) excluding four outliers.
MMSE score as dependent variable, IL-6 was not signiﬁcantly
associated with MMSE scores either before (b = 0.11, p = 0.54)
or after (b = 0.16, p = 0.41) excluding nine outliers.Fig. 1. Cerebrospinal ﬂuid (CSF) C-reactive protein (CRP) plotted against scores on
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Variables were
transformed to normal distribution before analysis. Dots represent the individual
PD patients. The correlation was signiﬁcant (Spearman’s Rho = -0.32 p = 0.004).
Since FACIT is an inverse rating scale, a negative correlation herein indicates that
the patients with higher levels of inﬂammatory markers display more severe
fatigue.
Fig. 2. Cerebrospinal ﬂuid (CSF) C-reactive protein (CRP) plotted against scores on
Hospital Anxiety and Depression Scale (HADS). Variables were transformed to
normal distribution before analysis. Dots represent the individual PD patients. The
correlation was signiﬁcant (Spearman’s Rho = 0.33, p = 0.002).
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We have previously measured serum levels of CRP, TNF-alpha,
and IL-6 in this sample of PD patients and in the reference group
(Lindqvist et al., 2012). We here found strong correlations between
CRP in CSF and CRP in blood in PD patients and in the reference
group (Spearman’s Rho = 0.57, p < 0.001, N = 115). There was a
trend for a signiﬁcant correlation between TNF-alpha in serum
and CSF (Spearman’s Rho = 0.17, p = 0.063, N = 119), but for IL-6,
the serum/CSF correlation was not statistically signiﬁcant (Spear-
man’s Rho = 0.13, p = 0.16, N = 116).4. Discussion
We here show, for the ﬁrst time, signiﬁcant associations be-
tween high levels of pro-inﬂammatory markers in CSF and severity
of fatigue, depression, anxiety and cognitive impairment in indi-
viduals with PD. Degree of neuroinﬂammation was signiﬁcantly
associated with more severe depression, fatigue, and cognitive
impairment even after controlling for appropriate confounders
such as age, gender, somatic illness and, when appropriate, demen-
tia diagnosis, and PD duration. We have previously reported asso-
ciations between peripheral inﬂammatory markers and severity of
depression and fatigue in this cohort of PD patients (Lindqvist
et al., 2012). We now demonstrate that these inﬂammatory
changes are present also in CSF. Given the limited permeability
of the blood brain barrier (BBB) for cytokines (Schiepers et al.,
2005), these ﬁndings are important as they show that relatively
higher levels of inﬂammatory markers, in direct contact with the
brain parenchyma, are associated with more severe symptoms of
depression and fatigue, as well as cognitive impairment. Interest-
ingly, higher levels of inﬂammatory markers were found in those
PD patients with dementia and more severe symptoms of depres-
sion and fatigue although we did not see this pattern in the PD
group as a whole.
Our ﬁndings are mainly in line with two previous PD studies
reporting associations between pro-inﬂammatory cytokines in ser-
um and symptoms of depression, fatigue, and cognitive impair-
ment (Lindqvist et al., 2012; Menza et al., 2010). Although we
did not see any signiﬁcant differences in inﬂammatory markers be-
tween the PD group as a whole and the reference group, a few ear-lier small-scale studies have reported higher CSF levels of pro-
inﬂammatory cytokines in PD patients compared to individuals
with other neurological disorders (Blum-Degen et al., 1995; Mogi
et al., 1996), and neurologically healthy controls (Mogi et al.,
1994). In line with our ﬁndings, however, a larger and more recent
study reported no differences in CSF levels of inﬂammatory mark-
ers Flt3 ligand and fractalkine between PD patients and healthy
controls (Shi et al., 2011). In addition to differences in sample sizes
and control group, other possible reasons for the divergent results
described above may be due to differences in sample preparation
and handling in the different studies. Several of the individuals
comprising the reference group were spouses of the PD patients,
and two were blood relatives. One may speculate that this may
have contributed to our failure to reject the null hypothesis, i.e.
some of the individuals in the reference group may share an
inﬂammatory endophenotype with some of the PD patients, or
may have been subjected to caregiver stress that could potentially
have inﬂuenced their cytokine levels. The individuals in the refer-
ence group, however, displayed none, or extremely mild, symp-
toms of depression, anxiety, and fatigue which suggest that they
were not likely to be under severe stress at the time of the CSF
sampling. Moreover, one may argue that the inclusion of spouses
in the reference group would be an advantage, since they share
the same environment as the patients, and any signiﬁcant differ-
ences between the two groups may therefore be considered more
disease speciﬁc. It is also noteworthy that a larger proportion of
the reference group had cardiovascular disease, which may have
increased cytokine values. We did, however, control for somatic ill-
ness in our analyses and this did not change the main results.
None of the above-mentioned studies attempted to distinguish
PD patients based on depressive or cognitive symptoms, nor inves-
tigate correlations between inﬂammatory markers and non-motor
symptoms. Previous clinical and population-based studies have
linked increased inﬂammation to depression, fatigue and cognitive
impairment in other neurodegenerative disorders. Worse cognitive
performance or cognitive decline has been associated with higher
blood or CSF levels of inﬂammatory markers in patients with vas-
cular dementia (Wada-Isoe et al., 2004) and Alzheimer’s disease
(AD) (Holmes et al., 2003). There is also some evidence from longi-
tudinal studies that high levels of inﬂammatory markers may indi-
cate increased future risk for developing vascular dementia and
progress from mild cognitive impairment to AD (Schmidt et al.,
2002; Westin et al., 2012). Based on these and other studies, a
‘‘cytokine model for cognitive function’’ has been suggested
(McAfoose and Baune, 2009). In line with this hypothesis, we found
that PDD patients had higher mean levels of CSF-CRP than the indi-
viduals comprising the reference group and non-demented PD pa-
tients, and this difference did remain signiﬁcant after controlling
for age, gender, and somatic illness. In depressed, non-parkinso-
nian patients, higher blood levels of pro-inﬂammatory cytokines
are commonly seen (Dowlati et al., 2010), and high CSF levels of
pro-inﬂammatory cytokine IL-6 have been associated with more
severe depressive symptoms in suicidal patients (Lindqvist et al.,
2009). Moreover, in individuals with leukemia and multiple sclero-
sis, symptoms of fatigue have consistently been associated with
higher levels of inﬂammatory markers in CSF and in the periphery
(Heesen et al., 2006; Meyers et al., 2005). In all, our ﬁndings that
more pronounced fatigue, depression, and cognitive impairment
is linked to higher levels of CSF inﬂammatory markers further
strengthens the hypothesis that these symptoms are associated
with neuroinﬂammatory mechanisms, regardless of diagnosis.
Higher cytokine levels in PD patients with more severe non-mo-
tor symptoms may be due to an increased peripheral production of
inﬂammatory markers crossing the BBB (Schiepers et al., 2005), or
augmented secretion by microglia and astrocytes within the cen-
tral nervous system (CNS) (Hanisch and Kettenmann, 2007; McG-
188 D. Lindqvist et al. / Brain, Behavior, and Immunity 33 (2013) 183–189eer and McGeer, 1995). CRP was the inﬂammatory marker that
showed the strongest association with non-motor symptoms in
our material; high CRP levels were signiﬁcantly associated with
more severe symptoms of fatigue and depression, as well as a
dementia diagnosis, even after controlling for potential confound-
ers. CRP has traditionally been viewed as one of the acute phase
reactants but studies have shown that CRP may also have direct
biological activities on vascular cells and monocytes/macrophages
(Yeh, 2005). CRP is mainly synthesized in the liver, however results
from post-mortem studies on patients with AD and intracerebral
hemorrhage suggest that CRP can be produced from within the
brain by neurons and glial cells (Di Napoli et al., 2012; Yasojima
et al., 2000). Interestingly, a recent animal study found that
microglial cultures produce CRP, suggesting that microglial cells
may be the source of CRP in the central nervous system (Juma
et al., 2011). We here found a strong correlation between CSF
and plasma CRP levels, providing important evidence that certain
inﬂammatory markers in the blood mirror inﬂammation in the
CNS. However, it is noteworthy that we did not ﬁnd any correlation
between IL-6 in blood and CSF. This has also been shown in previ-
ous studies (Lindqvist et al., 2009). Thus, potential future periphe-
ral biomarkers for CNS inﬂammation in PD should be carefully
selected based on their ability to cross the BBB and communicate
with the periphery.
Traditionally, psychiatric symptoms in PD have been thought to
be the result of either a reaction to the disability caused by PD or a
pathological mechanism associated with the neurodegenerative
process in PD. In this study we focused on neuroinﬂammation as
a pathophysiological mechanism potentially underlying the devel-
opment of such symptoms. To what extent a casual relationship
between neuroinﬂammation and depression can be inferred has
not been fully determined, but results from animal and clinical
studies do suggest such a relationship (Capuron and Miller, 2004;
Frenois et al., 2007). In the regression analyses conducted in the
present study, we found that higher CRP levels in CSF were signif-
icantly associated with severity of depression and fatigue, and high
MCP-1 levels were signiﬁcantly associated with severity of depres-
sion. These associations remained signiﬁcant even after taking into
account potential confounders such as PD duration, as a putative
indicator of disability or general burden of disease, and somatic ill-
ness. Thus, our results indicate that neuroinﬂammation may be
independently associated depression and fatigue in PD. In non-
PD patients with major depression, treatment with anti-inﬂamma-
tory components like the TNF-a antagonist inﬂiximab may reduce
depression in treatment-resistant depression patients with in-
creased baseline inﬂammatory status (Raison et al., 2013). Interest-
ingly, the effects of inﬂiximab on depressive symptoms may be
mediated by transcriptional regulation of for instance genes re-
lated to activation of the immune system (Mehta et al., 2013). If
cytokine antagonism could be useful for treatment of depression
in PD patients as well, remains to be investigated.
The potential roles of cytokines and chemokines in the genera-
tion of non-motor symptoms of PD are not yet completely under-
stood. On the one hand they promote immune activation, e.g. via
microglial activation and induction of leukocyte chemotaxis (Tan-
sey et al., 2007). In this capacity, chemokines and cytokines are clo-
sely associated with chronic neuroinﬂammation, potentially
leading to neuropsychiatric manifestations. Conversely, cytokines
and chemokines may have important functions as neuromodula-
tors under normal conditions (Vitkovic et al., 2000). There are
many different potential mechanisms by which pro-inﬂammatory
cytokines may generate symptoms of depression, fatigue, and cog-
nitive impairment. Cytokines may to have direct effects on mono-
aminergic neurotransmission (Dunn, 2006), the Hypothalamic–
Pituitary–Adrenal axis (Berczi et al., 2009), and the kynurenine
pathway of tryptophan degradation (Dantzer et al., 2008), allmechanisms that have been implicated in the pathophysiology of
depressive symptoms (Bao et al., 2007; Erhardt et al., 2013; Hirsch-
feld, 2000).
To summarize, this is the ﬁrst study to show that severity of
non-motor symptoms of PD are correlated with degree of neuroin-
ﬂammation, as indicated by high levels of pro-inﬂammatory mark-
ers in CSF. These results suggest that non-motor symptoms of PD
may be associated with neuroinﬂammatory mechanisms. If our re-
sults are reproduced by future studies it introduces the intriguing
possibility that anti-inﬂammatory medications may be used to
treat such symptoms speciﬁcally.5. Conﬂict of interest statement
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